Takashi Kei Kishimoto

Prior to joining Selecta Biosciences in 2011, Takashi Kei Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, Inc., where he served in several leadership positions from 2006 to 2011 and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease.

He served as Senior Director of Inflammation Research at Millennium Pharmaceuticals, Inc., from 1999 to 2006, where he provided the scientific leadership for four programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Takashi Kei Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell and The New England Journal of Medicine. Takashi Kei Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University.

Takashi Kei Kishimoto is the Chief Scientific Officer at Selecta Biosciences, based in United States, North America. With a background in Biotechnology, Takashi Kei Kishimoto has a rich history of leadership and innovation.Takashi Kei Kishimoto studied BA unknown at New College of Florida. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.